KEY WORDS TB skin testing; women; immunocompromised; HIV resurgence in the prevalence of tuberculosis (TB) has been observed since 1985 that has largely been attributed to the increasing prevalence of human immunodeficiency virus (HIV) infection. 1, 2 From 1985 through 1992, the number of reported TB cases increased 44% among persons aged 25-44 years, which was twice the rate observed overall in the United States during the same period. 3 These results indicated that TB may be an increasing problem among reproductive-aged women.
Presently in the United States, women account for the most rapid increase in the number of cases of HIV. 4 These women are largely indigent minority women from large urban areas who are also at increased risk for TB. Indeed These recommendations also would apply to pregnant women, although historically most obstetricians have deferred chemoprophylaxis until after delivery. This is primarily due to reports of an increased risk of hepatotoxicity from isoniazid in pregnant women with anergy. 18 Despite the risk of isoniazid hepatitis, some experts recommend that chemophaphylaxis be strongly considered after the first trimester for HIV-infected pregnant women with anergy. 3 Although TB skin testing along with an anergy panel has been widely used, little information exists as to the prevalence of anergy among women, specifically during pregnancy. Studies have demonstrated that CD4+T lymphocytes decline during normal pregnancy by approximately 100 cells/ mm3. lz, 3 Others have reported no difference in T lymphocyte subsets between HIV-infected and noninfected women. 19 Since anergy has been shown to be indirectly proportional to the CD4+T lymphocyte count, pregnant women would theoretically be more likely to have anergic test results. 8 In summary, despite the observed decrease in the CD4+T lymphocyte counts, pregnancy did not alter the prevalence of cutaneous anergy in our population of HIV-infected women. Questions regarding the reliability of anergy testing and the apparent lack of benefit of chemoprophylaxis for these patients should prompt reconsideration of routine anergy testing of the HIV-infected patient.
